Withdrawal or Reduction TKIs in CML-CP
NCT04143087 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2021-09-05
Summary
Compare MMR on 12 month treated with half TKIs(including imatinib, dasatinib, and nilotinib) or TKIs withdrawal.
Conditions
- MMR on 12 Month
Interventions
- DRUG
-
withdrawal TKIs or halve TKIs
Stop TKIs or treated by half TKIs
Sponsors & Collaborators
-
Nanfang Hospital, Southern Medical University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-10-23
- Primary Completion
- 2021-10-31
- Completion
- 2021-12-31
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
NCT01043874 ·Status: COMPLETED ·Phase: PHASE4
-
Nilotinib for First-line Newly Diagnosed CML-CP Patients
NCT03942094 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
NCT04795427 ·Status: COMPLETED ·Phase: PHASE2
-
Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
NCT04739826 ·Status: RECRUITING
-
Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib
NCT01400074 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
NCT00237120 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
NCT05311943 ·Status: UNKNOWN ·Phase: PHASE3
-
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
NCT04677439 ·Status: UNKNOWN ·Phase: PHASE4
-
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
NCT04155411 ·Status: UNKNOWN ·Phase: PHASE4
-
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
NCT05404516 ·Status: UNKNOWN ·Phase: PHASE2
-
Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI
NCT06121765 ·Status: NOT_YET_RECRUITING
-
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT05367765 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
NCT04933526 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation
NCT01744665 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
NCT02272777 ·Status: COMPLETED ·Phase: PHASE3
-
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
NCT00760877 ·Status: COMPLETED ·Phase: PHASE3
-
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
NCT01889407 ·Status: UNKNOWN
-
Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL
NCT03123887 ·Status: COMPLETED
-
Treatment Free Remission (TFR) in CML Patients （CML-CP）Study
NCT05440747 ·Status: NOT_YET_RECRUITING
-
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia
NCT04147533 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant
NCT00413270 ·Status: NO_LONGER_AVAILABLE
-
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT03723681 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
NCT00644878 ·Status: TERMINATED ·Phase: PHASE2
-
An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
NCT02174445 ·Status: TERMINATED ·Phase: PHASE3
-
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
NCT01819389 ·Status: COMPLETED ·Phase: PHASE3